Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2009 Aug 1.

Published in final edited form as: Mol Cancer Ther. 2008 Aug;7(8):2445–2454. doi: 10.1158/1535-7163.MCT-08-0063

A, p53-deficient (A9) or wild type (C8) MEFs was treated with HLI373 for 15 h. Cell death was assessed by trypan blue exclusion. B, A9 and C8 cells were incubated with HLI373 for 15 h and PARP assessed by immunoblotting. C, Human colon carcinoma HCT116-p53⁺ and HCT116-p53⁻ cells were treated with 1 μg/ml Adriamycin, 50 μM ALLN, or HLI373 for 46 h. D, The indicated cells were incubated with 25 μM HLI373 (upper) or 1 μg/ml Adriamycin (lower) for 30 h, and cell viability assessed. Results calculated based on cells specifically killed by the indicated treatment and represents average and standard error of three independent experiments [100 × (total cell death with drug treatment – background cell death) / (total viable cells without treatment)].

A, p53-deficient (A9) or wild type (C8) MEFs was treated with HLI373 for 15 h. Cell death was assessed by trypan blue exclusion. B, A9 and C8 cells were incubated with HLI373 for 15 h and PARP assessed by immunoblotting. C, Human colon carcinoma HCT116-p53⁺ and HCT116-p53⁻ cells were treated with 1 μg/ml Adriamycin, 50 μM ALLN, or HLI373 for 46 h. D, The indicated cells were incubated with 25 μM HLI373 (upper) or 1 μg/ml Adriamycin (lower) for 30 h, and cell viability assessed. Results calculated based on cells specifically killed by the indicated treatment and represents average and standard error of three independent experiments [100 × (total cell death with drug treatment – background cell death) / (total viable cells without treatment)].